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Copyright © 2008 JCBN Summary Coenzyme Q10 (CoQ10) is essential for ATP production in the mitochondria, and
is an important antioxidant in every biomembrane and lipoprotein. Due to its hydrophobicity,
a binding and transfer protein for CoQ10 is plausible, but none have yet been isolated and
characterized. Here we purified a CoQ10-binding protein from human urine and identified it
to be saposin B, a housekeeping protein necessary for sphingolipid hydrolysis in lysosomes. We
confirmed that cellular saposin B binds CoQ10 in human sperm and the hepatoma cell line
HepG2 by using saposin B monoclonal antibody. The molar ratios of CoQ10 to saposin B were
estimated to be 0.22 in urine, 0.003 in HepG2, and 0.12 in sperm. We then confirmed that
aqueous saposin B extracts CoQ10 from hexane to form a saposin B-CoQ10 complex. Lipid
binding affinity to saposin B decreased in the following order: CoQ10>CoQ9>CoQ7>>α-
tocopherol>>cholesterol (no binding). The CoQ10-binding affinity to saposin B increased with
pH, with maximal binding seen at pH 7.4. On the other hand, the CoQ10-donating activity of
the saposin B-CoQ10 complex to erythrocyte ghost membranes increased with decreasing pH.
These results suggest that saposin B binds and transports CoQ10 in human cells.
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Introduction
Coenzyme Q (CoQ) was first isolated as an essential
component of the mitochondrial respiratory chain [1] and
is present in all tissues [2, 3]. CoQ is thought to function
as a lipid-soluble, front-line antioxidant [2–4], and thus is
ubiquitously present in all biomembranes and lipoproteins.
CoQ also has many homologues with isoprene chains of
various lengths. For example, the isoprene chain is 10 units
(CoQ10) in length in humans and guinea pigs, but is 9 units
(CoQ9) in length in rats and mice.
CoQ is synthesized in the mitochondria, ER-Golgi system
and peroxisomes [2,  3], and therefore, CoQ needs to be
transferred intracellularly to other organelles and extra-
cellularly to lipoproteins. Radiolabeled CoQ has been
used to confirm this notion. The intravenous injection of
14C-labeled CoQ10 into guinea pigs confirmed uptake by
the liver, spleen and adrenal glands, and to a lesser extent, by
the kidney and heart [5]. Nakamura et al. intravenously
injected  14C-labeled CoQ10 into rats and measured its
content in subfractions of the rat heart [6] .  A t  2h  a f t e r
administration, radioactivity was found mostly in the
cytosolic fraction, followed by the mitochondrial, lysosomal,
microsomal and nuclear fractions at 72 h. At two days after
intraperitoneal injection of 3H-labeled CoQ10, uptake intoG. Jin et al.
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various organelles and cytosol of rat liver was confirmed [7].
Oral administration of deuterium-labeled CoQ10 in humans
has confirmed uptake into blood circulation [8]. Rosenfeldt
et al. measured cardiac mitochondrial CoQ10 levels in
patients undergoing cardiac surgery and found that levels
were significantly higher in patients orally administrated
CoQ10 (300 mg/day for two weeks) than in the placebo
control group [9]. These results clearly demonstrate that
CoQ10 is transferred intracellularly and extracellularly,
resulting in its ubiquitous presence throughout the body.
As CoQ is insoluble in water, the existence of a CoQ-
binding and transfer protein has been hypothesized but has
yet to be isolated and characterized. We focused on human
urine as it contains CoQ10 [10] and is relatively clean and
accessible. As expected, CoQ10 was bound to a protein in
human urine. We purified this CoQ10-bindng protein using
conventional purification methods. The amino acid sequence
analysis revealed the binding protein to be saposin B, which
is known to be present in all cells and activates lysosomal
sphingolipid hydrolase.
In this report, we demonstrate that the saposin B-CoQ10
complex is present in human cells and that saposin B
extracts CoQ10 from CoQ10 hexane solution to form the
saposin-CoQ10 complex. We also show the evidence that
saposin B functions as a CoQ10 transfer protein.
Materials and Methods
Lipid analysis
CoQ homologues and α-tocopherol concentrations were
determined using an HPLC-ECD system, as reported pre-
viously [11], with minor modification. Briefly, samples were
added to a 9-fold volume of HPLC grade 2-propanol (Fisher
Chemicals, Fairlawn, NJ), vigorously mixed and centrifuged.
Supernatants thus obtained were injected onto the HPLC-
ECD system. Mobile phase: 50 mM NaClO4 in methanol/
2-propanol (7/3, v/v); flow rate: 1.0 ml/min; analytical
column: KANTO RP-18 (L) GP, 5 µm × 150 mm × 4.6 mm
(Kanto Chemical, Tokyo, Japan); post-reduction column:
RC-10, 15 mm × 4 mm (IRICA, Kyoto, Japan); detector:
ECD (600 mV) NANOSPACE SI-1 (Shiseido, Tokyo, Japan).
Purification of urinary CoQ10-binding protein
Urine taken from healthy volunteers was pooled in the
presence of sodium azide. Urine (300 ml) was centrifuged at
1,600 × g for 10 min to remove precipitates. Supernatant
was applied to a PD-10 column (Amersham Biosciences,
Uppsala, Sweden) pre-conditioned with a buffer (20 mM
phosphate buffer containing 50 mM NaCl and 0.01%
sodium azide, pH 6.0) in order to remove salt and low
molecular weight substances. Obtained protein factions
were concentrated with an SC250 Express Speed VacR
(Thermo Savant, Holbrook, NY) and Centriplus YM-3
membrane (Millipore, Bedford, MA). Samples thus obtained
were applied to a DEAE sepharose Fast Flow column (bed
volume = 1.0 ml) (Amersham Biosciences) pre-equilibrated
with a start buffer (20 mM phosphate buffer containing
50 mM NaCl, pH 6.0). Proteins were eluted at a flow rate of
1.0 ml/min with an elution buffer (1.0 M NaCl in start
buffer, pH 6.0) using step-wise gradient of NaCl concentra-
tion. CoQ10 concentrations in each fraction were analyzed
by HPLC-ECD. CoQ10-rich fractions were concentrated
and were subjected to gel filtration (Superdex 200 10/300,
bed volume = 24 ml) (Amersham Biosciences). Proteins
were eluted with a buffer (50 mM phosphate buffer con-
taining 150 mM NaCl, pH 7.0) at a flow rate of 0.5 ml/min.
CoQ10 levels in each fraction were analyzed and CoQ10-
rich fractions were pooled. Concentrated fractions from
Superdex 200 were then applied to an octyl sepharose
column (bed volume = 1 ml) pre-equilibrated with a start
buffer (50 mM phosphate buffer, pH 7.0). Proteins were
eluted with an elution buffer (50 mM phosphate buffer
containing 2% n-octyl-β-D-glucoside) at a flow rate of
1.0 ml/min. CoQ10 concentrations were analyzed and
CoQ10-rich fractions were pooled.
Amino acid sequence
The purified protein was subjected to SDS-PAGE,
followed by electroblotting onto a PVDF membrane (ATTO,
Tokyo, Japan). The blotted membrane was stained with
Coomassie brilliant blue. Subsequently, the single stained
protein band was excised and analyzed using a gas-phase
protein sequencer (PPSQ-21; Shimadzu, Kyoto, Japan).
SDS-PAGE, Silver staining and western blotting
Samples were separated by electrophoresis through an
SDS/polyacrylamide gel (15% acrylamide). After electro-
phoresis, gels were stained with silver staining kits (ATTO).
For Western blotting analysis, proteins were transferred to
PVDF membranes. The membranes were incubated with
mouse anti-saposin B IgG for 1 h at room temperature.
Proteins were visualized with HRP-conjugated secondary
antibodies (Bio-Rad Japan, Tokyo, Japan).
Preparation of monoclonal antibody against saposin B
Six-week-old female BALB/c mice were immunized
subcutaneously with purified human saposin B (50 µg)
emulsified in Freund’s complete adjuvant for 7 times. Two
weeks later, the mice were injected intravenously with the
same antigen (25 µg). Three days later, serum was collected,
and spleen cells were fused with P3-X63-Ag8-U1 myeloma
cell line. Hybridoma clones were screened by ELISA
using purified saposin B. ELISA-positive hybridoma clones
were used for preparation of saposin B-specific antibody-
producing tumors in pristane (2,6,10,14-tetramethylpentade-
cane)-primed BALB/c mice. Ascites fluids containingCoenzyme Q10-Binding/Transfer Protein
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monoclonal antibody were clarified by centrifugation at
2,000 × g for 10 min and stored at −20°C. Immunoglobulin
class and subclass were typed with the MonoAB-ID kit
(Zymed, San Francisco, CA).
Preparation of HepG2 cells
Cultures of HepG2 cells (Dainippon Sumitomo Pharma,
Osaka, Japan) were maintained in Dulbecco’s MEM
(Sigma) supplemented with 10% fetal calf serum (HyClone,
Logan, UT), 100 units/ml penicillin, 100 µg/ml strepto-
mycin at 37°C in a humidified atmosphere of 5% CO2 and
95% air. At 80–90% confluence, cells were treated with
trypsin-EDTA (0.25% trypsin, 0.02% EDTA) at 37°C for
15 min. After addition of culture medium, cells were
centrifuged at 1,000 × g for 3 min at 4°C. Cells were washed
twice with ice-cold PBS, followed by homogenization in
lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 0.1%
nonidet P-40 (Nakarai Tesuque, Tokyo, Japan), 0.1 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml of
leupeptin, pepstatin A, N-tosyl-L-phenylalanyl chloromethyl
ketone, N-tosyl -L-lysyl chloromethyl ketone) and centrifu-
gation at 10,000 × g for 3 min at 4°C. The supernatant was
used for immunoprecipitation.
Preparation of human sperm
Human semen collected from healthy volunteers was
centrifuged at 3,000 × g for 10 min at 4°C. Precipitated
cells were then washed twice with PBS and homogenized in
lysis buffer, as described above.
Immunoprecipitation
Samples placed in protein LoBind tubes (Eppendorf,
Hamburg, Germany) were incubated with 5 µg of anti-
saposin B IgG or mouse normal IgG for 1 h at room temper-
ature. After incubation, 10 µl of protein G beads (Amersham
Biosciences) were added to samples, followed by further
incubation for 1 h. Beads were washed three times with
PBS. CoQ10 was extracted from beads with 2-propanol and
analyzed by HPLC-ECD. A SDS-PAGE sample buffer was
mixed with the beads and then applied to a Western blotting
analysis of saposin B.
Isoelectric point focusing chromatography
Isoelectric point (pI) focusing chromatography [12] was
performed by using the ProteomeLab PF 2D System
(Beckman Coulter). Initially the chromatofocusing column
was equilibrated for 130 min with start buffer (pH 8.5) at a
flow rate of 0.2 ml/min. Then, 0.16 mg of saposin B purified
from human urine was injected onto the equilibrated
column. After a stable baseline was established, the pH
gradient was started by introducing elution buffer (pH 4.0)
at a flow rate of 0.2 ml/min. Fractions were collected at
0.3 pH intervals and CoQ10 levels in each fraction were
measured. Finally, the column was washed with 1.0 M NaCl.
CoQ10-free saposin B and CoQ10-rebound saposin B were
analyzed similarly. CoQ10-free saposin B was prepared by
washing saposin B solution with 10 volume of hexane and
following centrifugation at 1,600 × g for 10 min. CoQ10-
rebound saposin B was prepared by mixing CoQ10-free
saposin B solution with 10 volume of hexane containing
10 mM CoQ10 and following centrifugation at 1,600 × g for
10 min.
Lipid binding assay
CoQ10-free saposin B (0.5 µM) in 50 mM phosphate
buffer (pH 7.4) containing 150 mM NaCl was vigorously
mixed for 5 min with hexane containing 10 mM lipids such
as CoQ10, CoQ9, CoQ7 and α-tocopherol, followed by
centrifugation at 1,600 × g for 10 min. Hexane was removed
and the aqueous layer was further centrifuged in Eppendorf-
tubes at 15,000 × g for 10 min to separate contaminating
hexane. Lipid concentrations in aqueous layer were analyzed
by HPLC-ECD. Human serum albumin was used instead of
saposin B for comparison. To investigate the pH dependence
of CoQ10-binding to saposin B, 150 mM NaCl containing
50 mM acetate buffer (pH 4.5) or 50 mM phosphate buffer
(pH 5.4, 6.4 or 8.0) were employed. Saposin B-free buffers
were used as blank.
CoQ10 donation activity assay
The crude saposin B fraction was purified on an ion
exchange column (DEAE sepharose) followed by a gel
filtration column (Superdex 200 10/300). Erythrocyte ghost
membranes were prepared by the method of Dodge et al.
[13]. Erythrocyte ghost membranes (10 µl), saposin B-
containing above buffer (1000 µl) were add to a glass vial
and incubated for 60 min with gentle shaking at 37°C. The
reaction mixture was transferred to Eppendorf-tubes and
centrifuged at 15,000 × g for 3 min at 4°C. The obtained
pellets were washed three times with 1.0 ml of buffer.
CoQ10 contents in ghost membranes were analyzed by
HPLC-ECD. Saposin B-free buffers were used as blank.
Statistical analyses
Data were analyzed by Student t test and values are
means ± SD. * and ** indicate significant differences
(p<0.05 and 0.01, respectively) between the two groups.
Results and Discussion
Purification and characterization of CoQ10-binding protein
We first confirmed the presence of CoQ10 in human urine
from 9 healthy donors. The concentrations ranged from 40–
120 nM. Desalted human urine (300 ml) was then loaded
onto a DEAE sepharose column. The protein elution profile
was determined by monitoring absorbance at 280 nm, asG. Jin et al.
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shown in Fig. 1A. The CoQ10 content in each fraction was
determined using an HPLC system with an electrochemical
detector (ECD) [11] and is shown in the figure. The CoQ10-
containing protein fractions indicated by the thick solid line
in Fig. 1A were collected and processed by gel filtration.
The majority of CoQ10 was eluted with a 20-kDa protein
fraction as shown in Fig. 1B. Because the fraction contained
several proteins, as determined by SDS polyacrylamide gel
electrophoreses (Fig. 2), the CoQ10-binding protein was
further purified using an octyl sepharose column (Fig. 1C)
and the CoQ10-containing fractions indicated by a thick
solid line were isolated. SDS acrylamide gel electrophoreses
revealed a single protein band having a molecular weight
of 10 kDa, thus suggesting that CoQ10 is bound to a protein
homodimer in urine. Table 1 summarizes the purification of
the CoQ10-binding protein.
We analyzed the N-terminal 20 amino acids of the purified
CoQ10-binding protein by Edman sequencing. The amino
acid sequence was GDV -QD YIQ MVT DIQ TAV RT,
which is identical to human saposin B (GenBank accession
number 1N69_A), according to the DNA Data Bank of
Japan. Saposin B is a heat-stable glycoprotein comprising 80
amino acids and a carbohydrate component (molecular
weights, 9100 and 3000, respectively), having a total
molecular weight of 12.1 kDa [14]. As 84 µg of the purified
saposin B contained 1.0 nmol CoQ10, the molar ratio of
CoQ10 to purified saposin B was calculated: 1.0 nmol/84
µg/12,100 g/mol = 0.14 (Table 1).
Saposin B is known to bind sphingolipids including
ganglioside and ceramide [14], as well as glycerophos-
pholipids such as phosphatidylcholine and phosphatidyli-
nositol [15]. This occurs because saposin B is present as a
Fig. 1. Chromatographic profiles of eluates from (A) DEAE
sepharose, (B) Superdex 200, and (C) octyl sepharose
columns utilized in the purification of saposin B from
human urine. Solid bar and dotted line indicate the
CoQ10 concentration in the fraction and protein concen-
tration estimated from absorption at 280 nm, respective-
ly. The broken solid line indicates the concentration of
NaCl (A) or n-octyl-β-D-glucoside (C) in the eluates.
The thick solid line indicates the fractions collected.
Fig. 2. SDS polyacrylamide gel electrophoresis of the proteins
in each collected fraction. Proteins were stained with
silver stain kits. Lane 1: Molecular weight markers;
Lane 2: Human urine; Lane 3: Fractions obtained from
DEAE column chromatography; Lane 4: Fractions
obtained from Gel filtration; Lane 5: Fractions obtained
from octyl sepharose.
Table 1. Typical purification of saposin B from 300 ml of human urine.
Step
Protein 
(mg)
CoQ10 
(nmol)
CoQ10/protein 
(nmol/mg)
CoQ10 recovery 
(%)
Purification factor
Starting material 17.4 7.43 0.43 100 1.0
DEAE Separose 2.56 3.53 1.38 47 3.2
Superdex 200 0.51 1.35 2.65 18 6.2
Octyl sepharose 0.084 1.00 11.9 13 28Coenzyme Q10-Binding/Transfer Protein
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shell-like dimer [16] possessing a hydrophobic cavity for
lipid binding. Therefore, it is not surprising that saposin B
binds CoQ10. However, CoQ10 binding to saposin B has
never been reported.
Saposin B and monoclonal antibody
Saposin B is a housekeeping protein necessary for
lysosomal sphingolipid hydrolysis [14]. Indeed, it is present
in almost every tissue examined [14] as well as blood plasma
[17]. CoQ10 is also present in these intra- and extracellular
spaces. To confirm the presence of the saposin B-CoQ10
complex in human tissues, we attempted to immuno-
precipitate saposin B using a monoclonal antibody and to
measure CoQ10 content in the precipitate. For this purpose,
we further purified saposin B from human urine and pre-
pared a monoclonal antibody. First, we applied this antibody
to desalted human urine passed through a PD-10 column,
and found that the precipitate contains both saposin B and
CoQ10, as shown in Fig. 3A. On the other hand, urine
precipitate using normal IgG contained little saposin B and
CoQ10 (Fig. 3A). We also prepared a polyclonal antibody
against human saposin B, and immunoprecipitation of human
urine with this antibody gave identical results.
Presence of saposin B-CoQ10 complex in human cells
Next, we immunoprecipitated cell lysates obtained from a
human hepatoma cell line (HepG2) using a monoclonal
antibody against human saposin B in order to confirm the
cellular presence of saposin B-CoQ10 complex. As shown in
Fig. 3B, anti-saposin B IgG, but not normal IgG, precipitated
both saposin B and CoQ10. The saposin B-CoQ10 complex
was found in the cytosol of HepG2 cells (data not shown),
thus suggesting that saposin B is a CoQ10-transfer protein. It
is noteworthy that the majority of exogenous radiolabeled
CoQ10 is recovered from the cytosol [6]. Additionally, we
detected the saposin B-CoQ10 complex in fresh human
sperm (Fig. 3C). Molar ratios of saposin B to CoQ10 were
calculated as 0.22 in urine, 0.003 in HepG2 cells, and 0.12 in
sperm, thus confirming that considerable amounts of CoQ10
are bound to saposin B in vivo. We also confirmed the
presence of the CoQ10-saposin B complex in HepG2 and
sperm using a polyclonal antibody against human saposin B.
Saposin B may not be the sole CoQ10 binding protein. In
fact, several other proteins are associated with the bindings
of CoQ10 (Fig. 1). Saposin B, together with saposins A, C
and D, are the proteolysis products of a common precursor
protein, prosaposin [14]. All four saposins contain about 80
amino acids and are structurally similar. They have six
cysteines and conserved prolines in identical positions.
Characterizing the associations between CoQ10 and
saposins A, C and D, as well as prosaposin, will require
further investigation.
Dissociation and recombination of CoQ10 and saposin B
In order to have biological significance, the saposin B-
CoQ10 complex must donate CoQ10 to areas of low CoQ10
concentrations and extract CoQ10 from areas of high CoQ10
concentration. We used hexane as a model lipid-carrying
space. When purified saposin B from human urine was
applied to a chromatofocusing column, saposin B and
CoQ10 were coeluted, as shown in Fig. 4A, indicating
that saposin B and CoQ10 are present as a complex. The
isoelectric point (pI) of the complex is 4.5, which is identical
to the reported pI value of saposin B [14]. We then washed
an aqueous solution (pH 7.0) of saposin B-CoQ10 complex
Fig. 3. Presence of saposin B-CoQ10 complex in (A) human
urine, (B) HepG2 cells and (C) human sperm. Solid
and open bars show the CoQ10 contents in immuno-
precipitates obtained with monoclonal anti-saposin B
IgG and normal IgG, respectively. Values are means ±
SD (n = 3). * and ** indicate significant differences
(p<0.05 and 0.01, respectively) between the two groups,
as analyzed by the Student t test. Upper panel shows the
results of Western blotting with monoclonal anti-saposin
B antibody.G. Jin et al.
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with 10 volumes of hexane, and injected the aqueous protein
phase onto the same column. Figure 4B shows that saposin
B was eluted, but CoQ10 had been removed. CoQ10 was
detected in the hexane phase, indicating that the saposin B-
CoQ10 complex donates CoQ10 to areas of low CoQ10
concentration.
We then incubated an aqueous solution (pH 7.0) of CoQ10-
free saposin B with 10 volumes of hexane containing
10 mM CoQ10. After vigorous mixing for 10 h, followed by
centrifugation, the protein solution was again loaded onto a
chromatofocusing column. Fig. 4C shows that saposin B
and CoQ10 were coeluted similarly to the original saposin
B-CoQ10 complex. The amounts of CoQ10 extracted by
saposin B for 5 min increased with CoQ10 concentration in
hexane (Fig. 5A). On the other hand, human serum albumin
was not able to extract CoQ10 from the hexane solution
(Fig. 5A). These data clearly indicate that saposin B extracts
CoQ10 from areas of high CoQ10 concentration, while
albumin does not.
Binding specificity and pH dependence
The above aqueous CoQ10-free saposin B solution and
hexane partition system was useful to examine the substrate
specificity and pH dependence of the binding. We selected
α-tocopherol and CoQ homologues, such as CoQ9 and CoQ7,
as binding substrates and the respective 10 mM hexane
solutions were incubated with aqueous CoQ10-free saposin
B solution (pH 7.4) for 5 min. The binding affinity was
found to decrease in the order of CoQ10>CoQ9>CoQ7>>α-
tocopherol (Fig. 5B) while no binding was observed with
cholesterol (data not shown). Figure 5C shows that the
binding affinity of CoQ10 to saposin B increased with pH,
before leveling off at neutral and alkaline pH levels. Peak
binding was observed at pH 7.4.
Transfer of CoQ10 from saposin B to erythrocyte ghost
membranes
When erythrocyte ghost membranes were incubated with
the saposin B-CoQ10 complex, CoQ10 was transferred to
the ghost membrane in a time-dependent manner before
equilibration at 60 min (data not shown). The amount of
CoQ10 transferred in 60 min increased with decreasing pH
(Fig. 5D), which was the opposite trend as seen with
CoQ10-binding affinity. Under our conditions, about 84% of
CoQ10 in saposin B was transferred to the ghost membranes
at pH 4.5. The intracellular pH is 8.0 in the mitochondrial
matrix and 7.0 in cytosol, while lysosomes are acidic.
Therefore, the transfer of CoQ10 from saposin B would
favor lysosomes, although even at neutral pH, small but
significant amounts of CoQ10 were transferred.
Saposin B and CoQ10 deficiency
The above data suggest that saposin B is a human CoQ10
binding/transfer protein. If this function of saposin B is of
physiological importance, saposin B knockout mouse should
show symptoms related to CoQ deficiency. Unfortunately,
such mice have not yet been established. However, it is also
possible to compare reports of human saposin B and CoQ10
deficiencies.
Human saposin B deficiency is a rare disease [18–21].
The onset of the disease was between 6 months and 6
years after birth. Typical symptoms are ataxia and motor
Fig. 4. Dissociation and rebinding of CoQ10 and saposin B, as analyzed by isoelectric chromatofocusing. The line and bar indicate
protein contents estimated from UV absorbance at 280 nm and CoQ concentration in the fractions, respectively. (A) Purified
saposin B (0.16 mg) containing CoQ10. (B) Protein solution washed three times with 10 volumes of hexane. (C) Aqueous phase
from washed protein solution mixed with 10 volumes of hexane containing 10 mM CoQ10.Coenzyme Q10-Binding/Transfer Protein
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deterioration followed by intellectual dysfunction, which
resembles metachromatic leukodystrophy. Patients with
CoQ10 deficiency are also rare, but show muscle mito-
chondrial myopathy and ataxia [22–24]. Thus, common
features of saposin B and CoQ10 deficiencies are ataxia
and motor deterioration. Future analysis of the cellular
distribution of CoQ10 in tissues from patients with saposin
B deficiency may thus confirm the physiological function of
saposin B for CoQ10 transport.
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